'Experimental / investigational' denials
The plan called the treatment experimental. Often misapplied — and reversible by citing FDA approval, peer-reviewed evidence, and specialty-society guideline support.
What this denial means
An experimental/investigational denial (CARC 55) means the plan classified the requested treatment as not yet proven safe and effective for the patient's indication. Plans use this designation broadly: it can apply to truly investigational therapies in clinical trials, OR to FDA-approved drugs being used off-label, OR to procedures that are well-established but not in the plan's covered list. Most experimental denials are appealable when the treatment has FDA approval (for the patient's indication or any indication), peer-reviewed support, or specialty-society guideline recognition.
How to appeal it
Experimental appeals win on three pillars: (1) FDA approval status — even off-label use of an FDA-approved drug is not 'experimental' per se if peer-reviewed evidence supports the use; (2) peer-reviewed literature — citations to published trials, observational studies, or meta-analyses supporting the requested treatment for the patient's specific indication; (3) specialty-society guideline support — NCCN compendium for oncology is particularly strong, as plans are required by federal law to follow the NCCN compendium for Medicare and many follow it for commercial too. Cite all three.
Frequently asked questions
What does “denied as experimental or investigational” mean?
An experimental/investigational denial (CARC 55) means the plan classified the requested treatment as not yet proven safe and effective for the patient's indication. Plans use this designation broadly: it can apply to truly investigational therapies in clinical trials, OR to FDA-approved drugs being used off-label, OR to procedures that are well-established but not in the plan's covered list. Most experimental denials are appealable when the treatment has FDA approval (for the patient's indication or any indication), peer-reviewed support, or specialty-society guideline recognition.
How do I appeal a 'experimental / investigational' denials?
Experimental appeals win on three pillars: (1) FDA approval status — even off-label use of an FDA-approved drug is not 'experimental' per se if peer-reviewed evidence supports the use; (2) peer-reviewed literature — citations to published trials, observational studies, or meta-analyses supporting the requested treatment for the patient's specific indication; (3) specialty-society guideline support — NCCN compendium for oncology is particularly strong, as plans are required by federal law to follow the NCCN compendium for Medicare and many follow it for commercial too. Cite all three.
Related
- CARC 55 — Procedure/treatment/drug is deemed experimental/investigatio…The carrier classified the treatment as experimental. Appealable when FDA-approved, peer-reviewed, o
- CARC 114 — Procedure/product not approved by the FDA.Procedure/product not approved by the FDA.
- CARC 188 — This product/procedure is only covered when used according t…This product/procedure is only covered when used according to FDA recommendations.
- ERISA §503ERISA §503 is the foundational federal appeal-rights statute for the ~135 million Americans on emplo
- ACA §2719 (PHSA §2719)ACA §2719 guarantees every non-grandfathered group + individual health plan a standardised internal
- Cancer treatmentsChemo, immunotherapy, CAR-T, proton, PET, off-label per NCCN
- Specialty biologicsHumira, Enbrel, Stelara, Skyrizi, Cosentyx, Rinvoq, Dupixent
- Genetic testingBRCA, hereditary cancer panels, NIPT, tumor profiling, MRD
- Rare disease — ERT, substrate reduction, gene therapyPompe, Fabry, Gaucher, MPS, Batten, NPC, PKU
- 'Duplicate therapy' denialsThe plan flagged your medication as duplicating another drug you're already taking. Appealable when
- 'Not FDA-approved' denialsThe plan says the drug or its specific use isn't FDA-approved. Distinct from 'experimental' — and ap
- 'Not medically necessary' denialsThe single most common appealable denial. The insurer says the treatment isn't medically necessary b
Sources
Appeal a 'experimental / investigational' denials denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com